Recently, a group of innovative enterprises such as Newborn Biotech, Baite Micro Medical, Shenluo Medical, Ladder Medical, Aikemai, and Futong Huizhi have successively completed a new round of financing, with single amounts ranging from tens of millions to hundreds of millions of yuan, covering popular fields such as precision nutrition, cardiovascular intervention, neural regulation, brain computer interface, and cardiac electrophysiology; Promote the high-quality development of biomedicine and high-end medical equipment in China.

---

1、 Newborn Biotech has completed a Series C financing of over 100 million yuan, creating a core barrier for dietary supplement raw materials with innovative drug standards

On March 16th, Nanjing Newborn Biotechnology Co., Ltd. officially announced the completion of a Series C financing of over 100 million yuan. This round is led by Mingxi Capital, with Guanggu Production Investment following suit, and two old shareholders, Yida Capital and Huaxi Yuanyou Fund, continuing to raise funds. The financing funds will be specifically used for the construction of new technology platforms, capacity expansion, and deepening of global commercialization.
As a leading enterprise in the research and development of dietary supplement raw materials, Newborn Biotech breaks the industry’s homogenization dilemma with innovative pharmaceutical grade research and development standards, builds five major patent systems for efficacy, compounds, etc., and creates a multi-path full field technology platform for synthetic biology, chemical synthesis, etc., to ensure high purity and large-scale delivery of products; It has formed a creative design team led by Shawn Wells, creating an “Intel Inside” style element brand system, with a research and development team accounting for over 30%, and core personnel with more than 20 years of industry experience.
At present, the company has served more than 500 clients worldwide, including 400 overseas clients, and has performed outstandingly in the high access markets of Europe and America. Founder Liao Qilin stated that she will continue to build technological barriers with innovative drug ideas, while investors highly recognize her multiple barriers such as patents and brands, as well as her platform based innovation capabilities, and are optimistic about her sustained growth potential in the field of precision nutrition raw materials.

---

2、 Baite Micro Medical has completed nearly 100 million yuan in Series B financing, deepening its focus on peripheral vascular and heart failure intervention

Shenzhen Baitewei Medical Technology Co., Ltd. announced the completion of nearly RMB 100 million in Series B financing, led by Tianshili Capital, with Qinzhi Capital as the co investor and Kaicheng Capital as the exclusive financial advisor. This round of financing will be specifically used for the research and development of innovative products in the field of peripheral vascular intervention and heart failure, the construction of industrialization bases, and market expansion, accelerating the clinical translation and commercialization of core products.
As a benchmark enterprise in the field of cardiovascular intervention medical devices, Baitewei focuses on the two high prosperity tracks of peripheral vascular intervention and heart failure, building differentiated technical barriers and a full cycle product matrix. In the field of peripheral vascular intervention, the company has formed a complete layout of “volume reduction+thrombectomy+access”, and its core products have clear domestic substitution value: the independently developed peripheral venous thrombectomy system is the only product in China that has been approved for the “Green Channel for Special Review of Innovative Medical Devices” qualification. Led by Director Lu Xinwu of the Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University, it has completed multi center clinical registration in China and is about to be approved for market; The pulmonary artery thrombectomy system approved in 2025 is the only self expanding stent thrombectomy system in China, benchmarking against overseas second-generation competitors. It has completely independent intellectual property rights and is simultaneously laying out arterial thrombus volume reduction products, committed to building the first brand of physical volume reduction for intravascular thrombosis at home and abroad.
Tianshili Capital pointed out that the company has a significant advantage in product differentiation due to its mastery of innovative materials science platforms and core manufacturing processes at the source; Qinzhi Capital emphasizes that its pipelines have high clinical value and domestic substitution space; Kaicheng Capital helps accelerate its pipeline research and commercialization process. It is reported that the company’s Zhongshan industrialization base will accelerate its operation, and the Beijing sales headquarters has been officially established, laying a solid foundation for subsequent large-scale development.

---

3、 Shenluo Medical has completed hundreds of millions of yuan in Series C financing, focusing on the dual track of neural regulation and brain computer interface

On March 16th, Hangzhou Shenluo Medical (a leading enterprise in the field of neural regulation and brain computer interface) announced the completion of hundreds of millions of yuan in Series C financing, led by Junlian Capital, with excess follow-up from old shareholders Aobo Capital, Boyuan Capital, and Guotou Chuanghe. The raised funds will be mainly used for the innovation iteration and global commercial layout of ultra micro neural regulation technology platforms and brain computer interface platforms.
Relying on core technologies such as chip integration and wireless portability, Shenluo Medical has formed a global leading advantage in the field of ultra miniaturization: its tibial nerve stimulation system implant is only 0.3cc, which is more than 90% smaller than similar international products, and its spinal nerve stimulation products are also superior to overseas benchmark enterprises; Simultaneously building three major technology platforms including short-term implantation and rechargeable IPG, forming a product matrix covering multiple indications such as pain and urinary disorders, including core products such as already launched SCS systems and under development closed-loop brain computer interfaces.
Both the leading investors and existing shareholders acknowledge its underlying technological barriers and believe that its ultra miniaturization technology, platform based innovation capabilities, and full indication layout have the potential to lead the development of the global neural regulation industry. In the future, it will accelerate the clinical translation of cutting-edge therapies and benefit patients with various neurological diseases.

---

4、 Ladder Medical has completed a strategic financing of 500 million yuan, accelerating its impact on the global leading position in brain computer interfaces

On March 13th, Shanghai Ladder Medical announced the completion of a strategic financing of 500 million yuan, led by Alibaba, followed by Guotou Chuanghe, and continued support from old shareholders such as Tencent and Yuanlai Capital, with Qifeng Capital serving as the exclusive financial advisor. It is reported that the company has raised over 1.1 billion yuan in financing in the past year, making it the first enterprise in the field of brain computer interfaces by Alibaba and Tencent. The financing funds will help accelerate its clinical advancement and technological breakthroughs.
As an implantable brain computer interface hard technology enterprise, Ladder Medical has mastered core technologies such as ultra flexible microelectrodes and wireless implants. Its 256 channel wireless high-throughput invasive brain computer interface system is the only similar product in China to enter the NMPA innovative medical device “green channel”, and has completed the first clinical implantation in China. The company plans to carry out large-scale multi center registration clinical trials within the year, and the total number of clinical implants is expected to surpass Neuralink by the end of the year.
At the same time, the company has laid out a closed-loop ultra-low damage deep brain nerve stimulation system, which has completed 4 clinical implants and plans to start clinical trials in 2027. The investors recognize its underlying technological barriers and clinical value, and with the support of large companies and “national team” capital, it will promote its technological transformation and accelerate its impact on the leading position in the global brain computer interface field.

---

5、 Aikemai Medical has completed a financing of over 100 million yuan, accelerating the commercialization of pulse electric field ablation systems

On March 13th, Aikemai Medical Equipment (Zhejiang) Co., Ltd. announced the completion of a financing of over 100 million yuan, led by a fund under Zhongjin Capital, with joint investment from Yuanjing Capital and well-known industry investors, and exclusive financial advisor from Xingqiao Capital. The raised funds will be specifically used for the research and commercialization of pulsed electric field ablation (PFA) systems, 3D mapping systems, and electrophysiological consumables, consolidating their advantages in the field of cardiac electrophysiology.
The technical barriers in the cardiac electrophysiology field are high, and there is a vast space for domestic substitution. PFA, as a new generation of non thermal ablation technology, is driving industry iteration. The core product PFA system of Aikemai was approved for market through NMPA’s innovative medical device “Green Channel” in May 2025. The immediate pulmonary vein isolation rate during surgery is 100%, and the success rate of 12-month follow-up is 87.7%. It can achieve selective ablation of myocardial tissue and avoid the risk of surrounding tissue damage.
The company has built a full product matrix of “3D equipment+consumables”, and its independently developed AI driven third-generation 3D mapping system has obtained ethical approval, which can work together with PFA system to improve surgical accuracy; Simultaneously layout the entire process of electrophysiological consumables to form a comprehensive solution. The investors recognize its technological barriers and clinical value, helping it accelerate commercialization and seize the opportunity in the domestic PFA market.

---

6、 Futong Huizhi received seed round investment and released the first ultrasound brain computer interface tFUS Mind in China

Shanghai Futong Huizhi announced the completion of a seed round of financing, led by Wuchuang Dazhi Group. The funds will be used for core technology research and development and product industrialization, and the first domestic ultrasound brain machine interface product, tFUS Mind, will be released simultaneously, achieving a dual breakthrough in financing and product release, demonstrating its technological accumulation in the field of ultrasound brain machine interfaces.
As the first ultrasound brain computer interface product in China, tFUS Mind strictly follows the relevant standards of the National Medical Products Administration for research and development, focuses on post-stroke motor dysfunction rehabilitation, and constructs a full process system of “precise positioning signal acquisition real-time decoding closed-loop regulation”, which can accurately capture central nervous system signals and achieve motion intention decoding. Its core advantages are significant: millimeter level precise positioning (with an error of about 1 millimeter), low-intensity ultrasound stimulation without long-term adverse reactions, combined with independently developed stereotactic helmets and AI driven technology, forming differentiated competitive barriers, and possessing multiple patents in China, the United States, and Europe, building a solid intellectual property defense line.
Wuchuang Dazhi stated that ultrasound brain computer interface is a key strategic direction for the 15th Five Year Plan, and the technical strength and product layout of Futong Huizhi are in line with the demands of the track; Futong Huizhi will promote product type testing and registration declaration, while opening up technical interfaces to promote industry win-win and help stroke patients recover.

---

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

Stay Connected

• • Website: https://www.meritsipglobal.com

• • LinkedIn: Follow us on LinkedIn

• • Email: info@meritsip.com

© 2025 MeritsIP. All Rights Reserved.